A single injection of the experimental agent nirsevimab ahead of respiratory syncytial virus (RSV) season protects healthy infants from lower respiratory tract infections associated with the pathogen, ...

The monoclonal antibody nirsevimab (Beyfortus) reduced hospitalizations among infants with respiratory syncytial virus (RSV)-associated lower respiratory tract infection, the randomized, pragmatic ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving them. Factors such as older maternal age, private insurance, and receipt of ...

The monoclonal antibody nirsevimab (Beyfortus) protected young infants against hospitalization for respiratory syncytial virus (RSV), pediatric intensive care unit (PICU) admissions, and mechanical ...

Please provide your email address to receive an email when new articles are posted on . Nirsevimab may offer protection for a period longer than a typical 5-month RSV season. Further investigation is ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers studied real-world data on the effectiveness ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden of ...

Nirsevimab is a long-acting monoclonal antibody to the RSV fusion protein that has an extended half-life. Positive results were announced from the phase 3 MELODY and phase 2/3 MEDLEY trials evaluating ...

The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc AZN and Sanofi SA's SNY nirsevimab has a favorable benefit-risk profile to prevent respiratory ...

Nirsevimab therapy is effective for reducing the risk for hospitalization for respiratory syncytial virus (RSV)-associated bronchiolitis among infants, according to a study published in the July 11 ...

After a 2022–2023 season marked by a severe epidemic of bronchiolitis due to respiratory syncytial virus (RSV), in particular in terms of emergency department visits and hospital admissions, on ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...